Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands

Cytokine and Growth Factor Reviews

Volumn 12, Issue 1, 2001, Pages 9-18

  Horowitz, Mark C ^a   Xi, Yougen ^a   Wilson, Kimberly ^a   Kacena, Melissa A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone resorption; Osteoblasts; Osteoclastogenesis

Indexed keywords

CARRIER PROTEIN; CELL RECEPTOR; GLUCOCORTICOID; GLYCOPROTEIN; MEMBRANE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TRANCE PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

AGING; ALBERS SCHOENBERG DISEASE; ANIMAL; BONE ATROPHY; BONE GROWTH; BONE MASS; BONE METASTASIS; BONE TURNOVER; CELL DIFFERENTIATION; FEMALE; HUMAN; HYPERPARATHYROIDISM; MALE; MENOPAUSE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PERIODONTAL DISEASE; POSTMENOPAUSE OSTEOPOROSIS; RHEUMATOID ARTHRITIS; SHORT SURVEY; SIGNAL TRANSDUCTION; STROMA CELL;

NON-PROGRAMMATIC;

ANIMALS; BONE RESORPTION; CARRIER PROTEINS; GLYCOPROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035070302     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(00)00030-7     Document Type: Short Survey

References (74)

1. Mesenchymal stem cells
2. Osteoblastic gene expression during adipogenesis in hematopoietic supporting murine bone marrow stromal cells
3. Adipocytic cells cultured from marrow have osteogenic potential
4. Macrophage colony-stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse
5. Advances in bone biology: The osteoclast
6. Modulation of osteoclast differentiation
7. Regulation of osteoclast function
8. Osteoblastic cells are involved in osteoclast formation
9. The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells
10. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
11. Identity of osteoclastogenesis inhibitor factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
12. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
13. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells
14. TR1, a new member of the tumor necrosis factor receptor family, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption
15. Characterization of structural domains of human osteoclastogenesis inhibitor factor
16. Osteoclastogenesis-inhibitor factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast
17. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines
18. Osteoprotegerin mRNA is increased by interleukin-α in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells
19. Tumor necrosis factor-α and -β upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells
20. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells
21. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Down-regulation by glucocorticoids
22. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6 stimulate osteoprotegerin ligand gene expression in human osteoblastic cells
23. 2 in human bone marrow stroma cells
24. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation
25. Transforming growth factor-β1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells
26. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
27. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
28. cAMP stimulates osteoblast-like differentiation of calcifying vascular cells. Potential signaling pathway for vascular calcification
29. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation: A possible explanation for the paradox of arterial calcification in osteoporotic patients
30. Cytokines and estrogen in bone: Anti-osteoporotic effects
31. The receptor for the cytotoxic ligand TRAIL
32. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
33. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
34. Osteoprotegerin (OPG) has potent and sustained anti-resorptive activity in postmenopausal women
35. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord
36. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
37. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection
38. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation
39. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
40. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun N-terminal kinase in T cells
41. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
42. Evidence for a role of a tumor necrosis factor-α (TNF-α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival
43. Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: Regulation of mRNA expression of osteoclast differentiation factor (ODF)
44. Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene
45. Identification of an OSF-2 binding site in the murine RANKL/OPGL gene promoter: A potential link between osteoblastogenesis and osteoclastogenesis
46. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation
47. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts
48. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanism of glucocorticoid-induced osteoporosis
49. ODF/OPGL expression is regulated by IL-1 and IL-6
50. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells
51. Transforming growth factor-β stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells
52. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell dependent mechanism involving c-JUN repression
53. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene
54. Granulocytemacrophage colony-stimulating factor corrects macrophage deficiencies, but not osteopetrosis, in the colony-stimulating factor-1-deficient op/op mouse
55. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene
56. The cell-surface form of colony-stimulating factor-1 (CSF-1) is regulated by osteotropic agents and supports formation of multinucleated osteoclast-like cells
57. Murine osteoclasts and B-lymphocytes share a common progenitor cell whose abundance in bone marrow is regulated by estrogen
58. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor λB (RANK) receptors
59. Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE
60. Estrogen deficiency induces bone loss by enhancing T-cell production of TNA-α
61. Tumor necrosis factor receptor family RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
62. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis
63. Structure and expression of the murine rank gene
64. Characterization of the intracellular domain of receptor activator of NF-λB (RANK)
65. The TRAF family of signal transducers mediates NF-λB activation by the TRANCE receptor
66. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis
67. Genetic linkage of familial expansile osteolysis to chromosome 18q
68. Tumor necrosis factor receptor-associated factors (TRAFs) - A family of adapter proteins that regulates life and death
69. Activation of NF-λB by RANK requires tumor necrosis factor receptor-associated factor (TRAF6) and NF-λB-inducing kinase. Identification of a novel TRAF6 interaction motif
70. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling
71. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice
72. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFNγ
73. Long term protection from wear debris-induced bone resorption and amelioration of established osteolysis by RANK;Fc
74. Selective inhibition of NF-λB activation by a peptide that blocks the interaction of NEMO with the 1λB kinase complex